Notes
Outline
2004 Interim Results
An Overview
Transatlantic Operations
2004 Interim Results
Oncology Highlights
2004 Interim Results
Neurotherapy and LentiVector Highlights
Oncology
Target Markets Worth >$3 billion
5T4 Cancer Technology
The Basis of TroVax and the Wyeth Collaboration
5T4 Targeted Antibody Therapy
Collaboration with Wyeth
TroVax
®
Recruiting the Immune System to Kill Cancer
TroVax
®
Broad Utility at Various Stages of Disease
TroVax
®
Clinical Development
TroVax
®
Phase I/II Results in Colorectal Cancer
TroVax
®
Phase I/II Patient Survival Summary
TroVax
®
Colorectal Cancer First Line Chemotherapy
TroVax
®
Phase II Trials in Colorectal Cancer with Chemo
TroVax
®
Phase II Trials in Colorectal Cancer with Chemo
TroVax
®
Interim Phase II Results in Colorectal Cancer
TroVax
®
Summary
MetXia
®
Enhancing Cyclophosphamide Prodrug Therapy
MetXia
®
Activating Cyclophosphamide at Tumour Site
MetXia
®
Clinical Development
MetXia
®
Phase I – Phase II Trial in Pancreatic Cancer
MetXia
®
Summary
Neurotherapy
Target Markets Worth ~$3 billion
LentiVector
®
The Key to Neurotherapy
ProSavin
®
Dopamine Replacement in Parkinson’s Disease
ProSavin
®
Completing Preclinical Package for Start of Trials
MoNuDin
®
Preclinical Efficacy in ALS
Innurex
®
Preclinical Efficacy in Nerve Repair
2004 Interim Results
Financial Highlights
2004 Interim Results
Summary Profit & Loss to 30 June 2004
2004 Interim Results
Exceptional Costs - Reorganisation
2004 Interim Results
Continuing Cost Control and Focus
2004 Interim Results
Summary Cash Flow to 30 June 2004
Financial Outlook
Sufficient Cash to 2007
Anticipated News Flow 2004-05
Oncology
Anticipated News Flow 2004-05
Neurotherapy
Summary
End
Notes
